Eli Lilly and Company (NYSE:LLY) is set to issue its quarterly earnings data before the market opens on Tuesday, October 24th. Analysts expect the company to announce earnings of $1.03 per share for the quarter. Eli Lilly and has set its FY17 guidance at $4.10-4.20 EPS.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 EPS. On average, analysts expect Eli Lilly and to post $4.16 EPS for the current fiscal year and $4.60 EPS for the next fiscal year.

Shares of Eli Lilly and Company (NYSE LLY) opened at 85.95 on Tuesday. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The firm’s 50-day moving average price is $83.56 and its 200 day moving average price is $82.19. The stock has a market capitalization of $90.68 billion, a P/E ratio of 37.19 and a beta of 0.34.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.42%. Eli Lilly and’s payout ratio is currently 90.04%.

TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/17/eli-lilly-and-company-lly-to-release-quarterly-earnings-on-tuesday.html.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 990,000 shares of company stock valued at $82,949,650. 0.20% of the stock is owned by company insiders.

LLY has been the topic of a number of recent analyst reports. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price target on the stock. in a report on Wednesday, July 26th. BMO Capital Markets reaffirmed a “sell” rating and set a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $93.00 price target on shares of Eli Lilly and in a report on Thursday, June 22nd. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Friday. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $88.97.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.